NCT03654612View on ClinicalTrials.gov

Apatinib Combined With S-1 for the Treatment of Recurrent/Metastatic Head and Neck Malignancies

PHASE1/PHASE2UnknownINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 16, 2018

Primary Completion Date

March 1, 2020

Study Completion Date

September 1, 2021

Conditions
Head and Neck Cancer
Interventions
DRUG

Apatinib

Apatinib 500mg qd plus S-1 50mg bid d1-d14/28d cycle

Trial Locations (1)

410011

RECRUITING

the Second Xiangya Hospital, Changsha

Sponsors
All Listed Sponsors
collaborator

Chinese Society of Clinical Oncology

OTHER

lead

China International Medical Foundation

OTHER